Association of Environmental Engineering and Science Professors

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting

Retrieved on: 
Thursday, March 2, 2023
American Association for the Advancement of Science, Annual general meeting, Association of Environmental Engineering and Science Professors, Research, CNS, Science (journal), National academy, Attention, MS, Multiple sclerosis, Central nervous system, National Academy of Sciences, PALO, AAAS, KTTA, Pharmaceutical industry, Science

AAAS is the world's largest general scientific society, with over 120,000 members, and is the publisher of the scientific journal Science.

Key Points: 
  • AAAS is the world's largest general scientific society, with over 120,000 members, and is the publisher of the scientific journal Science.
  • Prof. Steinman's research on the link between the Epstein-Barr virus and multiple sclerosis (MS) was a runner-up for the 2022 Science Magazine Breakthrough of the Year.
  • “I’m honored to be asked to address such an important assembly of scientists and to share insight on this critical work with peers,” commented Dr. Steinman.
  • “Recognition of the work by Science is thrilling because of the attention it brings to our effort to fight MS.”

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

Retrieved on: 
Thursday, February 23, 2023
KTTA, National Academy of Sciences, National academy, Research, Treatment, Great America Committee, Patient, Association of Environmental Engineering and Science Professors, CNS, Multiple sclerosis, Science, Epstein–Barr virus, PALO, Central nervous system, MS, Pharmaceutical industry

PALO ALTO, Calif. and MIAMI, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for Central Nervous System (CNS) disorders, today announced that Lawrence Steinman, Pasithea’s Chairman and National Academy of Sciences Professor, will deliver the Dr. Kenneth P. Johnson lecture at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) on February 23 in San Diego, California.

Key Points: 
  • PALO ALTO, Calif. and MIAMI, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for Central Nervous System (CNS) disorders, today announced that Lawrence Steinman, Pasithea’s Chairman and National Academy of Sciences Professor, will deliver the Dr. Kenneth P. Johnson lecture at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) on February 23 in San Diego, California.
  • The ACTRIMS Forum is a translational science meeting focusing on scientific discoveries made in multiple sclerosis (MS) to advance the understanding of research and clinical care of patients with MS.
  • The lecture allows attendees an opportunity to hear from a prestigious researcher selected for their contributions to multiple sclerosis.
  • Prof. Steinman’s research on the link between Epstein-Barr virus and multiple sclerosis was a runner-up for Science Magazine’s 2022 Breakthrough of the Year.

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award

Retrieved on: 
Thursday, February 16, 2023
Brain mapping, National academy, Physician, Central nervous system, Therapy, National Academy of Sciences, PET, SBMT, Research, PALO, CNS, Molecular mimicry, DSM-IV codes, Association of Environmental Engineering and Science Professors, Nobel Prize, Cure, Immunization, HEPACAM, KTTA, Pharmaceutical industry, Medical imaging, Medicine

This prestigious award is given by the SBMT and the World Brain Mapping Foundation to physicians, engineers, and scientists who have contributed significantly to the field of brain mapping and therapeutics.

Key Points: 
  • This prestigious award is given by the SBMT and the World Brain Mapping Foundation to physicians, engineers, and scientists who have contributed significantly to the field of brain mapping and therapeutics.
  • Past recipients include Nobel Prize winner Dr. Eric Kandel, and Dr. Michael E. Phelps, the pioneer of PET imaging.
  • “MS is a debilitating disease that requires research into effective therapies and innovation in immunization.
  • I dedicate my career to advancing these therapies for the thousands suffering from neurological diseases globally.”

Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and Symposium

Retrieved on: 
Monday, October 17, 2022
MIAMI, Immunology, University of Navarra, SEC, Therapy, Amyotrophic lateral sclerosis, Spinal cord, MS, Nerve, Autoimmune disease, Nobel Prize in Physiology or Medicine, Multiple sclerosis, Association of Environmental Engineering and Science Professors, National Academy of Sciences, RRMS, Optic nerve, Nobel Prize, NASDAQ, Neuroscience, Biotechnology, Psychopharmacology, Research, Program, ALS, Lists of diseases, Immunotherapy, University, Immune system, Immunization, Company, Department, Dana–Farber Cancer Institute, Neurology, CEO, University of Buenos Aires, Amyotrophy, CNS, GLOBE, Neurodegeneration, KTTA, Brain, DNA, Forward-looking statement, National academy, Noonan syndrome, Psychiatry, Central nervous system, Pharmaceutical industry, Medicine, Symposium

We look forward to presenting our data at an international forum with other world-renowned leaders in MS and immunotherapy, said Dr. Tiago Reis Marques, CEO, Pasithea.

Key Points: 
  • We look forward to presenting our data at an international forum with other world-renowned leaders in MS and immunotherapy, said Dr. Tiago Reis Marques, CEO, Pasithea.
  • The study results support the Companys ongoing commitment to the program and move us further along in our mission to uncover new and effective treatments for neurological disorders.
  • The field of neurology, particularly for disabling diseases such as MS, requires deep research into the nature of effective therapeutic and immunization solutions.
  • Pasithea Therapeutics is a biotechnology company primarily focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders.